Australian-based biotechnology company Opthea intends to raise A$10m ($7.63m) in gross proceeds from the rights offering of shares entitling holders to purchase one share for every 14 existing shares in the company.

The offering will involve 10.7 million shares priced at A$0.93 ($0.71) a share.

The company has concurrently announced a private placement of shares to raise A$35m ($26.7m) in gross proceeds.

The proceeds are intended to be used for conducting clinical trials and funding research and development (R&D) expenses to support the development of some of its pipeline drugs.

US-based biotechnology company Vical Incorporated and AnGes MG have entered a research agreement.

The two companies will research for a development programme targeting chronic hepatitis B as part of the agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"US-based biotechnology company Vical Incorporated and AnGes MG have entered a research agreement."

Japanese-based biotechnology company AnGes MG will provide funding for the programme in exchange for an option to negotiate exclusive rights to the programme in Japan, while Vical will conduct pre-clinical research related to the programme.

Sentien Biotechnologies has raised $12m in a series A financing round co-led by Boehringer Ingelheim Venture Fund USA (BIVF USA) and BioInnovation Capital.

The proceeds are intended to be used to fund the initial clinical development of its SBI-101 for the treatment of acute kidney injury (AKI).

Based in the US, Sentien Biotechnologies is focused on cellular therapies development.

French biotechnology company Biophytis has raised €15m ($16m) and €3.73m ($3.97m) respectively through a private placement of bonds and shares of its common stock.

The proceeds are intended to fund phase IIb SARA-OBS / SARA-INT clinical study on Sarconeos, the company’s leading product for the treatment of sarcopenia.